Elsulfavirine

Elsulfavirine (trade name Elpida; also known as VM 1500) is drug used to treat HIV infection. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI).^[1][2][3] Elsulfavirine is a prodrug which is metabolized to the active antiviral agent deselsulfavirine (also known as VM 1500A).^[4] It was developed by the Russian company Viriom.^[5]

Elsulfavirine

Clinical data
Trade names	Elpida
Other names	VM 1500; elpivirine
ATC code	None
Legal status
Legal status	Rx-only in Russia
Identifiers
IUPAC name N-[4-[[2-[4-Bromo-3-(3-chloro-5-cyanophenoxy)-2-fluorophenyl]acetyl]amino]-3-chlorophenyl]sulfonylpropanamide
CAS Number	868046-19-9
PubChem CID	11527519
DrugBank	14929
UNII	ZC4CGO0RUG
Chemical and physical data
Formula	C24H17BrCl2FN3O5S
Molar mass	629.28 g·mol−1
InChI InChI=1S/C24H17BrCl2FN3O5S/c1-2-21(32)31-37(34,35)17-4-6-20(19(27)11-17)30-22(33)9-14-3-5-18(25)24(23(14)28)36-16-8-13(12-29)7-15(26)10-16/h3-8,10-11H,2,9H2,1H3,(H,30,33)(H,31,32) Key:ULTDEARCBRNRGR-UHFFFAOYSA-N

In June 2017, elsulfavirine was approved for use in Russia as an oral formulation for the treatment of HIV-1 infections in combination with other antiretroviral drugs.^[4][6] Currently, elsulfavirine is used in antiretroviral therapy regimens in the Russian Federation, which includes the combination elsulfavirine + lamivudine (or emtricitabine) + tenofovir.^[7]

Long-acting injectable formulations of eslulfavarinin and deselsulfavarine are under investigation.^[8][9]

In addition, Roche is investigating the use of elsulfavirin for the treatment of COVID-19 and it is currently in Phase II clinical trials for this possible indication.^[5]